NEW YORK, Sept. 25 (GenomeWeb News) - Transgenomic will provide an additional supply of modified nucleic acid building-block compounds to Geron, which will use the technology to synthesize one of its thiophosphoramidate-based telomerase inhibitor cancer drugs.
Transgenomic CEO Collin D'Silva said the extended non-exclusive licensing agreement will enable Transgenomic to manufacture phosphoramidate-based oligonucleotides and the chemical building blocks required for their synthesis "for use in diagnostic and therapeutic applications by other biotechnology, pharmaceutical and diagnostics companies to the mutual benefit of both Transgenomic and Geron."
Geron said it will use the technology to help develop its cancer drug GRN163L, formerly known as GRN719.